Business
AtriCure Announces the First Patients Treated with Novel Dual Energy Platform
New technology combines Pulsed Field Ablation (PFA) and Advanced Radiofrequency Ablation with AtriCure’s EnCompass® clamp to reduce treatment time for
About this update from Atricure, Inc.
[{"type":"text","content":"\nNew technology combines Pulsed Field Ablation (PFA) and Advanced Radiofrequency Ablation with AtriCure’s EnCompass® clamp to reduce treatment time for surgical ablation patients\n\n MASON, Ohio--(BUSINESS WIRE)--\nAtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced successful first-in-human treatments using its novel dual energy platform that integrates Pulsed Field Ablation (PFA) with Advanced Radiofrequency Ablation (Advanced RFA). The procedures were performed by Dr. Adrian Pick in collaboration with the site Principal Investigator Professor Jayme Bennetts, at Victorian Heart Hospital in Australia under approval from the Monash Health Human Research Ethics Committee (HREC).\n\nThe new platform delivers the benefits of both technologies—combining the proven safety and effectiveness of radiofrequency (RF) ablation with the efficiency of PFA. Advanced RFA reduces ablation time significantly, while PFA enables transmural ablation in seconds. In the first two patients treated, total procedural ablation time to create a box lesion simultaneously isolating the pulmonary veins and the left atrial posterior wall was less than 60 seconds. Each ablation was also tested to prove acute electrical isolation.\n\n“For 25 years, we’ve been the leader in cardiac surgical ablation,” said Michael Carrel, President and CEO of AtriCure. “Our innovative EnCompass clamp technology was a significant step in streamlining cardiac surgery ablation procedures. Now, building on the proven performance of our EnCompass clamp, this platform offers the best of both worlds. By pairing Advanced RFA with PFA, we’re delivering unprecedented speed and flexibility for surgeons.”\n\nThe AtriCure Isolator® Synergy™ ablation system has a long history of safety and clinical effectiveness, supported by extensive published data, including over 100 publications, and has been used to treat over 450,000 patients in the last 20 years. AtriCure began development of the dual energy platform with the goals of shortening RF ablation times and introducing PFA as a complementary energy source. The system allows surgeons to use either modality independently or in combination.\n\n“This technology builds on AtriCure’s strong ...